Predictive BioSciences Obtains $25,000,000 Series C Funding

  • Feed Type
  • Date
    6/16/2010
  • Company Name
    Predictive BioSciences
  • Mailing Address
    128 Spring Street 400 Level B Annex Lexington, MA 02421
  • Company Description
    Predictive Biosciences is a molecular diagnostics company headquartered in Lexington, MA. Launched in 2006 with a $10 million Series A financing, the company was jointly founded by leading healthcare investors, experienced entrepreneurs, and internationally-renowned scientists in the areas of tumor growth, tumor angiogenesis, and cancer markers. Predictive Biosciences possesses an extensive IP portfolio – including 18 issued US patents – and deep in-house expertise in proteomics, diagnostics, oncology, and tumor biomarkers.
  • Website
    http://www.predictivebiosci.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the Series C financing will be used to complete multi-center clinical trials for Predictive’s CertNDx bladder cancer assay and support its commercial launch through the company’s CLIA certified laboratories.
  • M&A Terms
  • Venture Investor
    ProQuest Investments
  • Venture Investor
    Flybridge Capital Partners
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Highland Capital Partners
  • Venture Investor
    Kaiser Permanente Ventures

By posting a comment, you agree to our terms and conditions.